regulations.gov
Your Voice in Federal Decision-Making

Infectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification and Detection of Antimicrobial Resistance and Virulence Markers

Docket Folder Summary   🔁 **View all documents and comments in this Docket**

Docket ID: FDA-2016-D-0971   **Agency:** Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)

+ View More Docket Details

Primary Documents   View All (5)

N Infectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification... **Notice** **Posted:** 08/11/2016 **ID:** FDA-2016-D-0971-0005	Comment Period Closed Sep 12, 2016 11:59 PM ET
N Infectious Disease Next Generation Sequencing Based Diagnostic Devices: Microbial Identification... **Notice** **Posted:** 05/13/2016 **ID:** FDA-2016-D-0971-0001	Comment Period Closed Aug 11, 2016 11:59 PM ET
O Request for Extension from Advanced Medical Technology Association (AdvaMed) 📎 **Other** **Posted:** 08/15/2016 **ID:** FDA-2016-D-0971-0006	Comment Period Closed
O Request for Extension from Advanced Medical Technology Association (AdvaMed) 📎 **Other** **Posted:** 08/15/2016 **ID:** FDA-2016-D-0971-0007	Comment Period Closed
O Guidance for Infectious Disease Next Generation Sequencing Based Diagnostic Devices Microbial... 📎 **Other** **Posted:** 05/16/2016 **ID:** FDA-2016-D-0971-0002	**Comment Now!**

Supporting Documents

No documents available.

Comments   View All (10)

" *See Attached"* 📎 **View Comment** **Posted:** 08/24/2016 **ID:** FDA-2016-D-0971-0015	
" *The Critical Path Institute is submitting comments to this draft guidance on behalf of the members of the Critical Path to TB Regimens (CPTR). FDA is to be..."* 📎 **View Comment** **Posted:** 08/15/2016 **ID:** FDA-2016-D-0971-0010	
" *Please find attached comments from Microbiologics."* 📎 **View Comment** **Posted:** 08/15/2016 **ID:** FDA-2016-D-0971-0011	
" *See attached file(s)"* 📎	

View Comment   **Posted:** 08/15/2016   **ID:** FDA-2016-D-0971-0009

See attached file for full response - brief summary: Oxford Nanopore welcomes the initiative of the FDA to develop guidelines to inform the safe and effective..."

View Comment   **Posted:** 08/15/2016   **ID:** FDA-2016-D-0971-0013

Home

Search

Advanced Search

Browse By Category

Learn

About Us

eRulemaking Program

Media Toolkit

Agencies

Awards & Recognition

Enhancements & Fixes

Resources

Site Data

Regulatory Agenda

Agency Reports Required by Statute

API Overview

Developers

Help

How to use Regulations.gov

FAQs

Glossary

Connect With

✉ Contact Us

Privacy and Security Notice

User Notice

Accessibility Statement

Partner Sites | We the People | Federal Register | Reginfo | Congress.gov | USA.gov | E-Gov | Opengov

Participate Today!